Treatment of Sars-CoV2 infections (Covid-19) with valsartan vs placebo, a three-armed randomized, partly blinded trial
Not Applicable
Recruiting
- Conditions
- Covid-19
- Registration Number
- DRKS00021732
- Lead Sponsor
- Klinikum St. Georg gGmbH
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
Patients aged over 18 years with given consent, first positive Sars-Cov2 detection within the last three days
- Patients with pre-existing chronic renal insufficiency in any degree of severity
- Patients of both gender
Exclusion Criteria
- intolerance to RAS-I and ARB
- Contraindications against ACE/ARB according to current clinical standard
- History of falls (more than 2 falls in the last 8 weeks)
- Symptomatic hypotension (i.e. blood pressure < 100 mmHg systolic and/or 50 mmHg diastolic together with hypotensive symptoms)
- Acute renal failure from stage 2
- pregnancy
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method combined clinical improvement (7-category ordinal scale of clinical Status or Hospital discharge), daily assessment
- Secondary Outcome Measures
Name Time Method Secondary endpoints are collected post-hoc according to the availability of routine data. Mainly respiratory indices (Horovitz), virus load or PCR results, ventilation frequency, duration of hospitalisation and death are considered